文献速递系统性红斑狼疮

乌帕替尼单药或联合艾尔舒替尼治疗系统性红斑狼疮的疗效与安全性:长期扩展研究至104周结果

Efficacy and safety of upadacitinib as monotherapy or combined with elsubrutinib for the treatment of systemic lupus erythematosus: results through 104 weeks in a long-term extension study.
PubMed 文献 · RMD Open · 2025-08-18

该长期扩展研究纳入127例中重度活动性系统性红斑狼疮患者,评估乌帕替尼单药或联合艾尔舒替尼额外56周治疗的疗效与安全性。至第104周,各治疗组SRI-4、BICLA、LLDAS应答维持或增高,日糖皮质激素剂量降低,安全性特征与主研究相似。

要点

  • 第104周乌帕替尼组、乌帕替尼/艾尔舒替尼组、安慰剂转乌帕替尼/艾尔舒替尼组SRI-4分别为82.1%、85.4%、61.3%。
  • 第104周BICLA分别为69.2%、78.0%、54.8%,LLDAS分别为60.0%、78.0%、34.4%。
  • 第48至104周各组日糖皮质激素剂量均降低,发作发生率维持或进一步降低。

核心结论

  • 在中重度活动性SLE患者中,乌帕替尼单药和乌帕替尼/艾尔舒替尼联合治疗耐受性良好,并在104周内持续显示对SLE疾病活动度、糖皮质激素剂量和发作的有益效应。

研究设计与样本

  • 本研究为为期1年的长期扩展研究(NCT04451772),随访48周2期SLEek研究(NCT03978520),共纳入127例患者。
  • SLEek研究中随机接受乌帕替尼30 mg每日一次或乌帕替尼30 mg/艾尔舒替尼60 mg每日一次的患者在长期扩展研究中继续原分配治疗,原安慰剂组患者转为乌帕替尼/艾尔舒替尼治疗。
  • 评估至第104周,包括SRI-4、BICLA、LLDAS、糖皮质激素剂量较基线变化、发作事件和不良事件。

主要发现

  • 第104周SRI-4应答率:乌帕替尼组82.1%,乌帕替尼/艾尔舒替尼组85.4%,安慰剂转乌帕替尼/艾尔舒替尼组61.3%。
  • 第104周BICLA应答率:乌帕替尼组69.2%,乌帕替尼/艾尔舒替尼组78.0%,安慰剂转乌帕替尼/艾尔舒替尼组54.8%。
  • 第104周LLDAS应答率:乌帕替尼组60.0%,乌帕替尼/艾尔舒替尼组78.0%,安慰剂转乌帕替尼/艾尔舒替尼组34.4%。
  • 第48周至第104周,所有治疗组平均每日糖皮质激素剂量均降低,发作发生率维持或进一步降低。
  • 安全性特征与主SLEek研究中所观察到的相似。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This 1-year long-term extension (LTE) study (NCT04451772) followed the 48-week phase 2 SLEek study (NCT03978520) that evaluated upadacitinib (a Janus kinase inhibitor) alone or combined with elsubrutinib (a Bruton's tyrosine kinase inhibitor) in adults with moderately to severely active systemic lupus erythematosus (SLE). The objective was to evaluate the efficacy and safety of an additional 56 weeks of treatment. METHODS: Patients randomised to upadacitinib 30 mg one time per day (QD) or upadacitinib 30 mg/elsubrutinib 60 mg QD (upadacitinib/elsubrutinib) in the SLEek study continued their assigned treatment during the LTE. Patients originally receiving placebo switched to upadacitinib/elsubrutinib in the LTE. Assessments through week 104 included SLE Responder Index-4 (SRI-4), British Isles Lupus Assessment Group-based Combined Lupus Assessment (BICLA), Lupus Low Disease Activity State (LLDAS), change from baseline in glucocorticoid dose, flare events and adverse events. RESULTS: This LTE analysis included 127 patients. Efficacy responses for the groups receiving upadacitinib, upadacitinib/elsubrutinib and placebo to upadacitinib/elsubrutinib were maintained or increased from weeks 48 to 104 (week 104: SRI-4: 82.1%, 85.4% and 61.3%; BICLA: 69.2%, 78.0% and 54.8%; LLDAS: 60.0%, 78.0% and 34.4%). From weeks 48 through 104, the mean daily glucocorticoid dose was reduced, and the incidence of flares was maintained or further reduced in all treatment groups. Safety profiles were similar to those observed in the primary SLEek study. CONCLUSIONS: In this LTE study, upadacitinib monotherapy and upadacitinib/elsubrutinib combined were well tolerated and continued to demonstrate beneficial effects on SLE disease activity, glucocorticoid dose and flares through 104 weeks.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Merrill JT, Saxena A, Aringer M, et al. Efficacy and safety of upadacitinib as monotherapy or combined with elsubrutinib for the treatment of systemic lupus erythematosus: results through 104 weeks in a long-term extension study. RMD Open. 2025. PMID: 40829888. doi:10.1136/rmdopen-2025-005742

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。